Search
Afamelanotide
go.drugbank.com/drugs/DB04931Approved[L9086] It differs structurally from its endogenous counterpart by only two amino acids - these structural differences improve biological efficacy by imparting a greater affinity for its target and a longer
Terdecamycin
go.drugbank.com/drugs/DB19720ExperimentalThe usage of the INN stem '-mycin' in the name indicates that Terdecamycin is a antibiotic, produced by Streptomyces strain. Terdecamycin has a monoisotopic molecular weight of 585.31 Da.
Stallimycin
go.drugbank.com/drugs/DB20261ExperimentalThe usage of the INN stem '-mycin' in the name indicates that Stallimycin is a antibiotic, produced by Streptomyces strain. Stallimycin has a monoisotopic molecular weight of 481.22 Da.
Steffimycin
go.drugbank.com/drugs/DB19922ExperimentalThe usage of the INN stem '-mycin' in the name indicates that Steffimycin is a antibiotic, produced by Streptomyces strain. Steffimycin has a monoisotopic molecular weight of 574.17 Da.
Anthelmycin
go.drugbank.com/drugs/DB20238ExperimentalThe usage of the INN stem '-mycin' in the name indicates that Anthelmycin is a antibiotic, produced by Streptomyces strain. Anthelmycin has a monoisotopic molecular weight of 583.23 Da.
Bluensomycin
go.drugbank.com/drugs/DB20923ExperimentalThe usage of the INN stem '-mycin' in the name indicates that Bluensomycin is a antibiotic, produced by Streptomyces strain. Bluensomycin has a monoisotopic molecular weight of 585.25 Da.
Lydimycin
go.drugbank.com/drugs/DB21235ExperimentalThe usage of the INN stem '-mycin' in the name indicates that Lydimycin is a antibiotic, produced by Streptomyces strain. Lydimycin has a monoisotopic molecular weight of 242.07 Da.
Bimoclomol
go.drugbank.com/drugs/DB06258ExperimentalBimoclomol is an investigational drug that induces stress proteins and has cytoprotective effects.
Spectinomycin
go.drugbank.com/drugs/DB00919ApprovedVet approvedWithdrawnAn antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of gonorrhea.
Lecanemab
go.drugbank.com/drugs/DB14580ApprovedInvestigational[A253962,L44547] On January 6, 2023, lecanemab was granted accelerated approval by the FDA for the treatment of Alzheimer’s Disease.[L44547] It was granted full FDA approval on July 6, 2023.